

QUICKSILVER
SCIENTIFIC®

www.quicksilverscientific.com



Company profile

Quicksilver



Quicksilver Scientific uses a holistic approach bridging science and nature to help individuals achieve mind and body health. Quicksilver Scientific provide a range of products and protocols that have been designed to unburden the customer from toxins and aid them in transforming their health. The company innovates through modern science giving definition and direction to elements of natural health products that were simply empirical previously.

Quicksilver launched in 2005 and has experienced massive growth both in practitioner and consumer channels. The company has recently opened a new production facility in Louisville, Colorado to handle the increased demand. Quicksilver's liposomal supplements are highly bioavailable and are driving change in the market by raising the bar on supplement efficacy.

Quicksilver's Founder and CEO, Dr Christopher Shade (pictured), began his career in sustainability – including organic and biodynamic farming. He furthered his understanding of the environment's role in our health through his work with the Rodale Institute. He observed a depleted food system and saw supplements as a necessary addition to a healthy diet. Today, he and his team continue to develop products that boost the power of nature through science, helping people on their journey to optimal health. "Quicksilver products offer high bioavailability made possible by our proprietary delivery system that facilitates absorption of Vitamins and supplements into the bloodstream." – Dr Chris Shade.

Quicksilver Delivery Systems® improves upon basic liposomal delivery technology with smaller, more stable, tightly distributed single-layer

spheres (20-70nm) made from the highest-grade ingredients available. This nanoparticle delivery technology to enhance bioavailability and absorption of ingredients has been patented by the company. Although it is not manufacturing drugs, Quicksilver Scientific says it "uses the same high-tech equipment, rigorous processes, and tight particle size controls used by pharmaceutical companies. The swallowed vesicles have a higher uptake in the stomach and gastrointestinal tract as well. For compounds like curcumin and resveratrol it is a 25-to-300-fold increase in bioavailability. For the NAD+ supplement, the uptake is about four to four-and-a-half fold, meaning that taking 100 milligrams in this way is like taking 400 milligrams; for such an expensive supplement, this is good thing".

NAD+ Platinum™ launched in September 2020 and is now one of Quicksilver Scientific's flagship longevity products. Patent applications for this specific product are being prepared and Quicksilver Scientific have developed proprietary ratios of NAD+ precursors, to sirtuins activators and to methylation factors. The company continues to conduct product research through collaborations with George Washington University, Colorado State University and the Cleveland Clinic. The company has experienced steady growth in revenue since the launch of NAD+ Platinum™ and has successfully sold this product through both high-end retailers in Southern California and through its Amazon store front. Recently, Quicksilver partnered with Life Extension Europe, who now promote and sell Quicksilver Scientific products on its website. As a cGMP-certified facility, Quicksilver Scientific health supplements are manufactured according to cGMP regulations and strict quality-control guidelines. These FDA



guidelines are the standard in ensuring that products are designed, monitored and controlled at every stage of the manufacturing process. An important mandate of the company is full transparency with its customers. All batches produced undergo third-party testing to ensure that the safety, quality and potency of products uphold the high standards set by the company. Tests include certificates of analysis, potency tests, microbial tests, heavy metals tests, pesticide residue tests, particle sizing tests and ingredient identity tests.

NAD+ Platinum: target Hallmarks of Aging

NAD+ has potential link to all hallmarks of aging

Nicotinamide Mononucleotide (NMN): to increase cellular NAD+, support DNA repair, cellular bioenergetics, genomic signaling and epigenetic stability, mitochondrial function, and cell signaling and survival. Resveratrol and Quercetin: Phytochemicals that activate sirtuins, eliminate senescent cells, and activate the AMPK pathway to support proper nutrient sensing, mitochondrial function, and biogenesis. They also support proteostasis through the activation of nuclear sirtuins. TMG, B2, and B12: driving NAD+ production without methylation support can accumulate nicotinamide (NAM) and homocysteine. Accumulated NAM blocks sirtuins and consumes S-adenosylmethionine (SAMe), generating excess homocysteine. Thus, TMG, B2 and B12 support the re-methylation of homocysteine and the clearing of excess NAM.


Flagship product: deep dive

NAD+ Platinum™: product description

NAD+ Platinum™ is a comprehensive longevity product, activating multiple longevity mechanisms and pathways within the body. Quicksilver Scientific blends nicotinamide mononucleotide (NMN), a stable, direct precursor to NAD+, resveratrol and quercetin to hyperactivate sirtuins and combat cellular senescence, and TMG, B2, and B12 for methylation support. The product uses Quicksilver Scientific's patented nanoparticle delivery technology to enhance bioavailability and absorption of ingredients. Wrapped in a nanoemulsion particle, the liquid formula diffuses through mucosal membranes of the mouth and upper GI, moving quickly into blood circulation and cells, bypassing digestion.

NAD+ Platinum™: Preclinical and Clinical Studies

Currently engaged in a 50-person, clinical study, assessing the efficacy of NAD+ platinum. The company is looking at a range of longevity markers in the trial participants including epigenetic markers such as the Horvath biological age clock, sirtuins protein levels and activity, Klotho, NAD+ and NADH levels in serum and in cell extracts, senescent cells, inflammatory markers, AMPK and mTOR.



NAD+ Platinum™: ingredients and dosage

Ingredient	Scientific Evidence
NMN 50mg	NMN in an NAD+ precursor
Riboflavin 5mg	B Vitamins help support balanced methylation and keep the NAD+ cycle turning.
Vitamin B12 250mcg	B Vitamins help support balanced methylation and keep the NAD+ cycle turning.
Trimethylglycine, Quercetin Dihydrate, Resveratrol Proprietary blend	Resveratrol and quercetin help supercharge longevity proteins to support genome integrity and optimal cellular functioning

NAD+ Platinum™: Safety and risks

No side effects have been observed. All batches are produced in cGMP facilities and undergo third-party testing to ensure that the safety, quality, and potency of products uphold the high standards set by the company.

NAD+ Platinum™: Target market

Because NAD+ production is dependent on complex chemical cofactors and processes, the ingredients in NAD+ Platinum support the body's foundational physical and mental health and performance. Quicksilver Scientific believes NAD+ platinum has profound benefits, supporting everything from easing the aging process, to enhancing cellular-level energy to aiding cognitive, immune, and metabolic functions. In addition, the company believes that its liposomal delivery system is unique in sending the master blend behind NAD+ Platinum™ directly to thirsty cells.



Success Factors

Team and Reputation

- Dr Chris Shade, PhD, specialises in the biological, environmental and analytical chemistry of mercury in all its forms and its interactions with sulphur compounds, particularly glutathione and its enzyme system. He patented a mercury speciation diagnostic process to analyse human toxicity and founded the only clinical lab in the world that offers this testing. His time in nutraceuticals led him to design cutting edge systems for detoxification and antioxidant protection, including advanced phospholipid delivery systems for both fat- and water-soluble compounds. He also developed Quicksilver Delivery Systems® nanoparticle technology to increase the bioavailability of supplements for a more efficacious product;
- Quicksilver Scientific recently announced a strategic partnership with Truss CBD USA, a joint venture between Molson Coors and HEXO Cannabis, to provide its technology in the production of CBD beverages;
- Quicksilver Scientific have partnered with Life Extension Europe, and its products can be purchased through the Life Extension Europe website;
- Quicksilver Scientific have several partnerships with universities and clinics that will enhance its product research. George Washington University is currently using Quicksilver Scientific Mercury Tri-test in their research, Colorado State University are studying the companies hemp products and Cleveland Clinical are using Quicksilver scientific products in its studies;
- Quicksilver Scientific have created an affiliate programme, through its relationship with the AWIN network, which allows publishers and influencers the opportunity to earn commissions on Quicksilver Scientific consumer orders. This programme could significantly enhance marketing opportunities.

Intellectual Property

- There is a range of liposomal delivery methods in the supplement market, but some use grades of phospholipids such as raw lecithin, or shearing methods that result in large (200–600nm) particles which are not as well absorbed. Quicksilver Delivery Systems® uses smaller, more stable, tightly distributed single-layer spheres (called unilamellar vesicles); these have the potential to be small enough to begin being absorbed in the mouth, meaning the harsh environment of the gut is partially avoided;
- Due to the delivery systems, Quicksilver have claimed that its products can begin working within 5 minutes and progress to full exposure in 20-30 minutes. The company believes the enhanced bioavailability allows the customer to feel immediate effects of the products, and to prove its confidence in their products, they come with a 30-day consumer money back guarantee;
- Quicksilver Scientific already have over 50 products and is planning further expansion of its longevity line in the near-term. Through its research and development programs, the company suggests that it is planning new patents for capsule-based deliveries, including expansion of its AMPK, mitochondrial lines and telomere extension through the nano-delivery of cycloastragenol.

Funding

- No funding information was provided at this time.

Quicksilver Scientific: success grid

Intellectual property: Information for this page is only available within the full report.	Team: Information for this page is only available within the full report.	Unique value proposition: Information for this page is only available within the full report.
Efficacy: Information for this page is only available within the full report.		
Target: Information for this page is only available within the full report.		Competitive advantage: Information for this page is only available within the full report.
Customer segments: Information for this page is only available within the full report.	Channels: Information for this page is only available within the full report.	Runway: Information for this page is only available within the full report.
Inflection point: Information for this page is only available within the full report.		

 = Positive progress  = Work-in-progress  = Needs attention



About us

The report has been produced by the Market Intelligence Unit of LongevityTechnology – the number one online destination for daily news on the growing longevity market.

As a brand of First Longevity Limited, we bring together innovators and investors to commercialise the companies that will form the longevity economy.


There are already 100+ rejuvenation biotechs working on unique therapies and building R&D pipelines to increase healthspan and lifespan.


At the same time, all around the world, innovators are releasing nanobots, reprogramming nerve signals and applying AI to create exciting and scalable contributions to human longevity.

As a team we look beyond rejuvenation therapies to embrace other technologies that participate in the longevity investment category: agetech, xenotransplantation, biomarkers, AI, bioprinting, neuroceuticals, GRAS supplements ... over the coming period we will be publishing regular reports.

There are multiple technologies that contribute to the reduction of morbidity and the extension of lifespan: they will provide investors and innovators with both risks and returns. We're here to help analyse, report and educate.

You can find information about our next reports by visiting: <https://longevity.technology/product-category/analysis/>





**We bring together innovators
and investors to commercialise
the companies that will form
the longevity economy.**

www.Longevity.Technology

Copyright 2021 First Longevity Limited. All rights reserved. Longevity.Technology and its associated logo is a trademark of First Longevity Limited and the subject of trademark applications or registrations in various countries around the world. All other trademarks are the property of their respective owners.

Disclaimer: First Longevity Ltd publishes market research reports on various industry sectors. All reports purchased via the website, email or over the phone are subject to the following disclaimer. A purchase automatically indicates acceptance of the disclaimer. The information on this document is provided for information purposes only. It does not constitute any offer, recommendation or solicitation to any person to enter into any transaction or adopt any investment strategy, nor does it constitute any prediction of likely future movement in market activity or timing. Users of this document should seek advice regarding the appropriateness of investing in any securities, financial instruments or investment strategies and should understand that statements regarding future prospects may not be realised. Opinion and estimates are subject to change

without notice. We, at First Longevity, gather information from various sources such as face-to-face interviews, paid databases, annual reports, surveys and media releases. This information is collated in good faith and used on an as-is-and-as available basis by us. Our reports should only be construed as guidance. We assert that any business or investment decisions should not be based purely on the information presented in our reports. We will not be responsible for any losses incurred by a client as a result of decisions made based on any information included in the reports. We do not guarantee or take responsibility for the accuracy, completeness, reliability and usefulness of any information. In many cases, the opinion expressed in the reports is our current opinion based on the prevailing market trends and is subject to change. The information provided by us is for the sole use of the authorised recipient(s). No part of the information or service may be duplicated or transmitted in any manner or by any medium without prior permission from First Longevity. Any such act will be considered as the breach of the multi-user licence under which the report has been purchased.